Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Earnings for Kiniksa Pharmaceuticals, Ltd. (KNSA)
Earnings in 2023 (TTM): $-16,652,000
According to Kiniksa Pharmaceuticals, Ltd.'s latest financial reports the company's current earnings (TTM) are $-16,652,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Kiniksa Pharmaceuticals, Ltd.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-16,652,000 | $14.08 M |
| 2022 | $11.03 M | $183.36 M |
| 2021 | $-156,539,000 | $-157,924,000 |
| 2020 | $-156,229,000 | $-161,381,000 |
| 2019 | $-163,914,000 | $-161,867,000 |
| 2018 | $-103,441,000 | $-103,227,000 |
| 2017 | $-64,871,000 | $-64,873,000 |
| 2016 | $-23,937,000 | $-23,973,000 |